Page last updated: 2024-11-04

sulfamethoxypyridazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfamethoxypyridazine is a sulfonamide antibiotic that was first synthesized in the 1950s. It is used to treat bacterial infections, particularly urinary tract infections. The compound works by inhibiting the synthesis of dihydrofolic acid, an essential nutrient for bacteria. Sulfamethoxypyridazine is effective against a wide range of bacteria, including Escherichia coli, Staphylococcus aureus, and Streptococcus pyogenes. The compound is generally well-tolerated, but side effects such as nausea, vomiting, and diarrhea may occur. It is important to note that sulfamethoxypyridazine is not effective against all types of bacteria, and resistance to the drug has been reported. Sulfamethoxypyridazine has been studied extensively for its effectiveness in treating urinary tract infections. The drug is generally well-tolerated and effective in this indication. However, it is important to use the drug only as directed by a healthcare professional, as excessive use can lead to the development of antibiotic resistance.'

Sulfamethoxypyridazine: A sulfanilamide antibacterial agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfamethoxypyridazine : A sulfonamide consisting of pyridazine having a methoxy substituent at the 6-position and a 4-aminobenzenesulfonamido group at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5330
CHEMBL ID268869
CHEBI ID102516
SCHEMBL ID93617
MeSH IDM0020751

Synonyms (185)

Synonym
MLS001148433
BRD-K00938507-001-05-3
benzenesulfonamide, 4-amino-n-(6-methoxy-3-pyridazinyl)-
4-amino-n-(6-methoxy-pyridazin-3-yl)-benzenesulfonamide
smr000018386
DIVK1C_000239
KBIO1_000239
SDCCGMLS-0003277.P003
4-amino-n-[6-(methyloxy)pyridazin-3-yl]benzenesulfonamide
SPECTRUM_001151
PRESTWICK_118
NCGC00016324-01
SPECTRUM5_001187
BPBIO1_000714
BSPBIO_000648
OPREA1_275757
BSPBIO_002983
IDI1_000239
AB00052228
4-amino-n-(6-methoxypyridazin-3-yl)benzenesulfonamide
80-35-3
sulfamethoxypyridazine
4-amino-n-(6-methoxy-3-pyridazinyl)-benzenesulfonamide
MLS000100719
D02439
lederkyn (tn)
sulfamethoxypyridazine (inn)
NCGC00022232-04
NCGC00022232-03
quinoseptyl
sulfamethoxipyridazinum
3-methoxy-6-sulfanylamidopyridazine
sulfalex
davosin
3-p-aminobenzenesulphonamido-6-methoxypyridazine
kynex
solfametossipiridazina [dcit]
sulfamethoxypyridazine [inn]
vinces
durox
sulfdurazin
sulfametoxipiridazine
6-sulfanilamido-3-methoxypyridazine
myasul
retamid
3-(p-aminobenzenesulfamido)-6-methoxypyridazine
slosul
depovernil
brn 0277076
lisulfen
sulfametoxipiridazina [inn-spanish]
einecs 201-272-5
sulfapyridazine
3-sulfa-6-methoxypyridazine
opinsul
sulfanilamide, n(sup 1)-(6-methoxy-3-pyridazinyl)-
3-sulfanilamide-6-methoxypyridazine
paramid supra
sulphamethoxypyridazine
kinex
piridolo
rp 7522
sulfozona
petrisul
spofadazine
paramid
smop
cl 13494
sultirene
midikel
medicel
retasulfin
n(sup 1)-(6-methoxy-3-pyridazinyl)sulfanilamide
lentac
3-sulfanilamido-6-methoxypyridazine
lederkyn
altezol
midicel
longin
4-amino-n-(6-methoxy-3-pyridazinyl)benzolsulfonamid
sulfamethoxypyridazinum [inn-latin]
6-methoxy-3-sulfanilamidopyridazine
MLS000069641 ,
KBIO2_001631
KBIOSS_001631
KBIOGR_000760
KBIO2_004199
KBIO2_006767
KBIO3_002483
SPECTRUM2_001429
PRESTWICK0_000724
SPECTRUM4_000430
PRESTWICK1_000724
NINDS_000239
SPBIO_002587
SPECTRUM3_001462
SPBIO_001538
SPECTRUM1501156
PRESTWICK3_000724
PRESTWICK2_000724
NCGC00016324-02
AC-12005
HMS2092J05
n-(6-methoxy-3-pyridazinyl)sulfanilamide
S0591
4-amino-n-(6-methoxy-3-pyridazinyl)benzenesulfonamide
nsc-757875
retasulphine
CHEMBL268869
cl-13494
AKOS000605846
HMS500L21
FT-0653623
HMS1921L17
HMS1570A10
CHEBI:102516 ,
sulfametoxipiridazina
3-(4-aminobenzenesulfonamido)-6-methoxypyridazine
6-methoxy-3-pyridazinylsulfanilamide
sulfamethoxipyridazine
n(1)-(6-methoxy-3-pyridazinyl)sulfanilamide
sulfamethoxypyridazinum
solfametossipiridazina
A839894
HMS2097A10
pharmakon1600-01501156
nsc757875
cas-80-35-3
dtxsid5023611 ,
tox21_110373
dtxcid203611
n1-(6-methoxy-3-pyridazinyl)sulfanilamide
HMS2234F17
S4250
CCG-38976
NCGC00016324-05
NCGC00016324-04
NCGC00016324-03
NCGC00016324-06
sulfamethoxypyridazine [usp:inn:ban]
nsc 757875
t034e4ns2z ,
5-25-12-00424 (beilstein handbook reference)
unii-t034e4ns2z
EPITOPE ID:122239
SCHEMBL93617
NCGC00016324-09
tox21_110373_1
sulfamethoxypyridazine [who-dd]
sulfamethoxypyridazine [who-ip]
sulfamethoxypyridazine [mi]
sulfamethoxypyridazinum [who-ip latin]
sulfamethoxypyridazine [mart.]
CS-4821
mfcd00057372
W-104237
kineks
pyridazine, sulfamethoxy-
VLYWMPOKSSWJAL-UHFFFAOYSA-N
3-methoxy-6-sulfanilamidopyridazine
sulfanilamide, n1-(6-methoxy-3-pyridazinyl)-
benzenesulfonamide,4-amino-n-(6-methoxy-3-pyridazinyl)-
HY-B1387
AC-32613
OPERA_ID_698
AB00052228_12
SR-01000000179-3
sr-01000000179
sulfamethoxypyridazine, vetranal(tm), analytical standard
HMS3652H21
sulfamethoxypyridazine, analytical standard
sulfamethoxypyridazine, european pharmacopoeia (ep) reference standard
sulfamethoxypyridazine 100 microg/ml in acetonitrile
SR-01000000179-4
SBI-0051666.P002
HMS3714A10
SW196429-3
gtpl12686
DB13773
Q7636177
BRD-K00938507-001-13-7
D70409
NCGC00016324-08
sulfamethoxypyridazine 1000 microg/ml in acetonitrile
BS-32820

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" gondii, were treated with acetylspiramycin (ASPM) alone, 8 mg/mouse/day, per os, or in combination with an immunopotentiator (CSP-II), 10 mg/mouse/day, intraperitoneally, or sulfamethopyrazine (SMPZ), 2 mg/mouse/day, per os, for a period of 4 weeks."( [Studies on the therapeutics of experimental toxoplasmosis. II. Effect of acetylspiramycin alone or in combination with an immunopotentiator (CSP-II) or sulfamethopyrazine on Toxoplasma multiplication in the heart of mice acutely and chronically infected
Espinas, FM; Odakura, Y; Sakurai, H; Sasaki, H; Suzuki, N; Takei, Y, 1982
)
0.26

Bioavailability

ExcerptReferenceRelevance
" The absorption rate of the free forms of sulfanilamides was increased (significantly for sulfalen and sulfapyridazine)."( [Sulfanilamide absorption and acetylation in rats with experimental hyperlipidemia and cellular regulation of the process of acetylation].
Lubiankina, SV; Makarov, VA; Suetina, IV; Vasilenko, IuK; Vaskanian, VL,
)
0.13
" Oral treatment showed that the maximum plasma concentration was reached 17 hours post drug administration and that the bioavailability ranged around 57%."( [Pharmacokinetics and plasma protein binding of sulfamethoxypyridazine in camels (Camelus dromedarius)].
Abdennebi, EH; Ben Goumi, M; Bousfiha, A; Oukessou, M, 1994
)
0.54
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The dosage regimen in goats would be 37."( Serum disappearance and urinary excretion of sulfamethoxypyridazine in goats.
Garg, SK; Rivière, JE; Uppal, RP, 1994
)
0.55
"Derivative and difference spectrophotometric methods are described for the direct simultaneous analysis of combinations of Trimethoprim with sulfonamide drugs (sulfadiazine, sulfamethoxazole, sulfamethoxypyridazine) in commercial dosage forms."( Analysis of Trimethoprim--sulfonamide drug combinations in dosage forms by UV spectroscopy and liquid chromatography (HPLC).
Andrisano, V; Bonazzi, D; Cavrini, V; Di Pietra, AM, 1994
)
0.48
"0 mg/kg/day (10 rats per dosage and drug)."( Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.
Hughes, WT; Killmar, J, 1996
)
0.29
" To achieve and maintain serum concentrations 25 micrograms/mL, a rational dosage regimen of SMP for goats would be 55 and 38 mg/kg body weight as the loading and maintenance doses, respectively, with a dosage interval of 24 h by the sc route."( Bioavailability of sulfamethoxypyridazine following intramuscular or subcutaneous administration in goats.
Garg, SK; Uppal, RP, 1997
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
EC 2.5.1.15 (dihydropteroate synthase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyridazines
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency94.56250.044717.8581100.0000AID485294
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency18.83360.001022.650876.6163AID1224838
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.00290.000229.305416,493.5996AID743069
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
survival motor neuron protein isoform dHomo sapiens (human)Potency0.04470.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.00350.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (89)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID750784Antimicrobial activity against Salmonella typhi ATCC 23564 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID750777Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID750781Antimicrobial activity against Salmonella typhi ATCC 23564 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID599143Lipophilicity, log P of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID750789Antimicrobial activity against Staphylococcus aureus ATCC 11632 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID750773Antimicrobial activity against Escherichia coli ATCC 35218 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID750788Antimicrobial activity against Bacillus cereus MTCC 7350 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID750785Antimicrobial activity against Bacillus cereus MTCC 7350 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID750780Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID64418Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.41983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID750792Antimicrobial activity against Staphylococcus aureus ATCC 11632 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID750776Antimicrobial activity against Escherichia coli ATCC 35218 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (593)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990525 (88.53)18.7374
1990's21 (3.54)18.2507
2000's11 (1.85)29.6817
2010's25 (4.22)24.3611
2020's11 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.39 (24.57)
Research Supply Index6.58 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (2.72%)5.53%
Reviews12 (1.72%)6.00%
Case Studies33 (4.72%)4.05%
Observational0 (0.00%)0.25%
Other635 (90.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]